Background: The global obesity epidemic has created new challenges, including
| INTRODUCTION
The World Health Organization has reported an obesity epidemic affecting many countries, even developing, poor nations.
1 According to the Centers for Disease Control, the prevalence of obesity in the United States in the 12-19 year age range has already nearly doubled from 10.5% (1988) (1989) (1990) (1991) (1992) (1993) (1994) to 20.6% (2013-2014) , while extreme obesity (defined as ≥ 120th percentile) has tripled from 2.6% (1988) (1989) (1990) (1991) (1992) (1993) (1994) to 9.1% (2013) (2014) . 2 Similar to obese adults, obese adolescents have a higher risk of venous thromboembolism (VTE) compared to nonobese adolescents. [3] [4] [5] [6] [7] As the global obesity epidemic continues, there will be a greater need to treat overweight and obese adolescents for VTE. This population poses a dosing dilemma when prescribing lowmolecular-weight heparins (LMWH)-commonly enoxaparin.
There is little data to guide providers on how to dose enoxaparin in overweight and obese adolescents. First, the recommendations by the American College of Chest Physicians (ACCP) for weight-adjusted dosing of enoxaparin to treat pediatric VTE are based largely on adult studies, despite reduced predictability of the anticoagulant effect in children compared to adults when using weight-adjusted dosing. 8, 9 Thus, enoxaparin is used off label in children. Second, obesity can affect the pharmacokinetics of enoxaparin, although it is unclear if the net effects warrant dose modifications. [10] [11] [12] [13] [14] Third, the therapeutic ranges recommended by the College of American Pathologists have not been validated in clinical trials. 15 Finally, the monitoring of enoxaparin utilizing anti-Xa levels in adults is controversial, and no data exist for adolescents. 16, 17 Adolescent VTE, most commonly deep vein thrombosis (DVT) and pulmonary embolism (PE), patterns and mortality rates are different compared to adult VTE. 18 For example, PE in adolescents is rarely fatal and likely secondary to fewer comorbidities in the adolescent population. 19 In addition, adult dose-reduction strategies such as dosecapping may not apply for an obese adolescent who weighs less. 12, 13, 20 Because of these differences, data from obese adolescents is necessary and should not be extrapolated from trials designed for obese adults.
To our knowledge, there has been no study describing dose modifications in obese adolescents diagnosed with VTE. Two case series described enoxaparin prophylaxis in obese adolescents, not treatment. 21, 22 The small numbers in those studies limit the interpretation of their enoxaparin pharmacokinetic data.
At our institution, the Pediatric Hematology/Oncology (PHO) team is consulted for all adolescent patients diagnosed with VTE. The initial dosing of enoxaparin is determined and ordered at a pediatric hematologist's discretion with some patients receiving doses less than the ACCP's recommendations. After approval by the institution's institutional review board, we performed a retrospective cohort study with the primary goal of describing dosing, anti-Xa levels, and outcomes of overweight and obese adolescents who received upfront reduced dosing (RD) of enoxaparin. We also compared these patients to overweight and obese adolescents treated at our institution who received standard dosing (SD) to determine if future trials to evaluate the efficacy and safety of dose reduction are warranted. This database was queried using the terms "thrombosis," "thrombus," "DVT," "vein," "clot," "PE," "pulmonary," "emboli," and "stroke."
| MATERIALS AND METHODS

| Study population and data
The electronic and written medical records from hospitalization and/ or outpatient follow-ups were reviewed. Patients were included if they were ≥12 and ≤18 years old; overweight or obese, defined as a body mass index (BMI) ≥ 85th percentile for age and sex The duration of anticoagulation treatment varied depending on the scenario (ie, spontaneous or provoked). 25 Furthermore, the duration of enoxaparin used during the treatment time frame varied. As current VTE treatment recommends three months of therapy, the final dose (and final anti-Xa level) in our study was defined as the last prescribed dose (and level) at 90 days of treatment. 
| Anti-Xa levels and dose adjustments
At our institution, anti-Xa levels drawn after the 2nd through 5th doses 
| Outcomes
Retrospective reviews of radiology reports and medical records were performed to determine progression and bleeding, respectively. A progression was defined as thrombus extension, the development of a new PE, or re-thrombosis in a previously treated site, occurring after the initiation of enoxaparin. Based on medical record descriptions, bleeding events occurring 24 hours after enoxaparin initiation were classified as major if they were associated with a decrease in hemoglobin of ≥2 g/dL within 24 hours of the bleeding event or resulted in a blood transfusion. Bleeding events that did not satisfy the criteria for major based on medical record descriptions, were classified as minor. 
| Statistical analyses
| RESULTS AND DISCUSSION
The initial database query resulted in 276 patients. Electronic and written medical record review resulted in 42 patients, 12 of which were excluded for cerebral venous thrombosis (4), recent trauma or surgery (3), or renal disease (5), leaving 30 patients in our study group.
Twenty-seven patients were hospitalized for initial VTE management.
Of these 27 hospitalized patients, three were transferred from outside institutions on enoxaparin plus warfarin (2) or heparin infusion ( . Available unconjugated bilirubin levels (n=20), were below 6 mg/dL, the threshold shown to interfere with anti-Xa level assays. 26 Twenty-nine patients were reportedly negative for antithrombin III deficiency.
Nineteen patients initially received RD enoxaparin (Table 1) (Table 2) . Of these four, two patients who were initially dosed at <0.7 mg/kg had thrombus progression despite one patient having an initial supra-therapeutic anti-Xa level. Two bleeding events occurred, both of which were minor (Table 1) . Progression is defined as thrombus extension, the development of PE that was not present at diagnosis, or re-thrombosis in a previously treated site after initiation of enoxaparin and prior to completing therapy.
Eleven patients received SD (Table 1) . Unlike the RD patients, the SD patients' mean final dose was significantly lower than their mean initial dose (Figure 1 ). Notably, in eight patients whose final doses were less than their initial doses, six (75%) were dose reduced secondary to supra-therapeutic anti-Xa levels obtained 2-16 days from initiation of therapy.
Between the two groups, no significant differences were observed in demographics, obesity status, type of VTE, and use of thrombolysis (Table 1) . Despite a significantly lower mean initial dose in the RD group compared to the SD group, the mean initial anti-Xa levels and mean final doses were similar between the groups (Table 1 ). There were no significant differences in the percentages of patients who had initial sub-therapeutic, therapeutic, or supra-therapeutic anti-Xa levels, the number of anti-Xa levels obtained during 90 days of treatment, nor in progression or bleeding rates between the two groups ( Table 1) .
In prior LMWH studies, the reported incidence of progression ranged from 1-7% 27, 28 , and the reported incidence of bleeding ranged from 0-36%. 27 Ultimately, 83% of all patients were on RD at the end of treatment or at 90 days from diagnosis (n=25, mean dosing 0.73 ± 0.11 mg/kg), with therapeutic or supra-therapeutic anti-Xa levels.
These findings suggest that initial doses calculated using actual body weight may be greater than what is needed, which is consistent with some previously published reports. 12, 13, 26 Therapeutic or supratherapeutic anti-Xa levels were achieved in 74% of the RD group.
However, the degree of dose reduction should be cautiously considered as the two RD progressions occurred in patients who were initially dosed at <0.7 mg/kg.
Though the role of anti-Xa monitoring for enoxaparin in adult is controversial, monitoring in our SD patients showed supra-therapeutic levels up to 16 days from the initial dose. The significance of this is unknown as our sample size is small, but may be secondary to the effects that obesity has on enoxaparin pharmacokinetics that have yet to be clearly defined. [10] [11] [12] [13] [14] Until there are more studies regarding the utility of anti-Xa levels, overweight individuals should have periodic monitoring, possibly during the first 2 weeks of therapy. 16, 17 All bleeding events in our study were minor. Compared to the RD group, the SD group had a higher percentage. This is more likely secondary to the small sample size and less likely secondary to overdosing in the SD group; two of the three SD group patients had therapeutic anti-Xa levels during the bleeding events. 
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